GlassScriptPhysician profile
Kamran Tabaddor
NPI 1942216510
$3,192.80
in general payments reported to CMS, 2019-2025
33 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $730 · 2021: $299 · 2022: $465 · 2023: $307 · 2024: $222 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $662.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $321.84 | 2019-2023 | Rytary |
| Adamas Pharmaceuticals, INC. | $257.30 | 2019-2021 | |
| Lundbeck LLC | $235.09 | 2019-2023 | Rexulti |
| Kyowa Kirin, INC. | $214.88 | 2022-2024 | Nourianz |
| Lilly USA, LLC | $213.98 | 2020-2025 | Kisunla, Amyvid |
| Otsuka America Pharmaceutical, INC. | $207.32 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Avanir Pharmaceuticals, INC. | $160.18 | 2019 | |
| Genzyme Corporation | $154.28 | 2019-2021 | |
| Emd Serono, INC. | $139.18 | 2019-2020 | |
| Abbvie INC. | $109.78 | 2023-2024 | Botox, Ubrelvy |
| Biogen, INC. | $105.90 | 2020-2023 | Tysabri, Vumerity |
| Teva Pharmaceuticals USA, INC. | $100.12 | 2020-2022 | |
| Abbott Laboratories | $99.98 | 2020 | |
| Csl Behring | $96.76 | 2019-2020 | |
| Sk Life Science, INC. | $85.65 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $78.60 | 2019-2025 | Daybue |
| Biohaven Pharmaceutical Holding Company LTD. | $70.63 | 2022 | |
| Akcea Therapeutics, INC. | $58.40 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $55.78 | 2020 | |
| Sunovion Pharmaceuticals INC. | $54.71 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $50.82 | 2019 | |
| Acorda Therapeutics, INC | $44.79 | 2019 | |
| Grifols USA, LLC | $43.64 | 2019-2020 | |
| Ucb, INC. | $33.28 | 2021 | |
| Neurocrine Biosciences, INC. | $32.21 | 2023 | Ongentys, Ingrezza |
| Janssen Pharmaceuticals, INC | $31.74 | 2020 | |
| Ge Healthcare | $24.69 | 2022 | |
| Amgen INC. | $23.83 | 2019 | |
| Mallinckrodt Hospital Products INC. | $21.67 | 2020 | |
| Assertio Therapeutics, INC. | $17.92 | 2020 | |
| Sumitomo Pharma America, INC. | $17.89 | 2023 | Aptiom |
| Novartis Pharmaceuticals Corporation | $17.88 | 2019 | |
| Upsher-Smith Laboratories LLC | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamran Tabaddor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.